Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PESF (P. eryngii polysaccharide from solid-state fermentation) is a polysaccharide extracted from the fruiting bodies of *Pleurotus eryngii* (king oyster mushroom). It is produced through solid-state fermentation using lignocellulosic wastes such as corn-cobs and wheat bran. PESF has demonstrated lipid-lowering effects by significantly inhibiting foam-cell formation in murine macrophage cells and reducing lipid accumulation during the lipid absorption phase in a zebrafish hyperlipidemia model. Studies have shown that PESF has no detectable toxicity. It is being investigated for its potential use as a valuable lipid-lowering food additive or as a raw material for producing lipid-lowering drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PESF.